Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

View Category
Structural heart disease

Is TAVR Beneficial in Cardiogenic Shock?

The presence of cardiogenic shock (CS) in a setting of aortic stenosis ranges from 1% to 4%....
solaci -
Learn More
Antithrombotic Anticoagulants

Acute Pulmonary Thromboembolism: When Anticoagulation Alone May Not Be Enough

In recent times, pulmonary thromboembolism (PTE) has been the subject of growing research due to its persistent...
solaci -
Learn More
Structural heart disease

Impella in High Risk Coronary Angioplasty before TAVR

The population is aging, which is closely related with the presence of aortic stenosis. This condition, as...
solaci -
Learn More
Mitral valve

TCT 2023 | CLASP IID Study 1-Year Results: PASCAL vs. MITRACLIP for Degenerative Mitral Regurgitation

The negative impact of mitral regurgitation (MR) on patient mortality, morbidity, and quality of life is widely...
solaci -
Learn More
Structural heart disease

TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus

Degenerative aortic stenosis (AS) is the most common valve condition. A significant number of AS patients presents...
solaci -
Learn More
Mitral valve

TCT 2023 | TRILUMINATE Trial: Health Status after TriClip

Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure...
solaci -
Learn More
Structural heart disease

TCT 2023 | PARTNER 3 Low Risk: 5-Year Follwup

TCT has presented the 5-year clinical and echocardiographic outcomes of low-risk patients with severe aortic stenosis treated...
solaci -
Learn More
Mitral valve

TCT 2023 | EXPAND G4

The EXPAND G4 is a prospective multicenter single arm study on real life patients.  It included a total...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy